Drug firm Alkem Laboratories today said the US health regulator has issued an establishment inspection report (EIR) for its Daman facility.
Company's manufacturing facility at Daman was inspected from March 19 to March 27, 2018, by the United States Food and Drug Administration (USFDA), Alkem Laboratories said in a filing to BSE.
"In response to the Form 483 issued by the USFDA containing 13 observations, the company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines," it added.
The inspection has now been closed by the US health regulator, Alkem Laboratories said.
Shares of Alkem Laboratories today closed at Rs 2,026.35 per scrip on BSE, up 7.65 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)